The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The transaction is expected to close in the first quarter of 2022
The brand is now available pan-India through their distribution partner
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Biogen paid Ionis a US $ 60 million one-time upfront payment
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Partnering to build biosynthesis processes and a pharmaceutical production platform
Subscribe To Our Newsletter & Stay Updated
